Avoro Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,674,835
| Closed | -$171M | – | 33 |
|
|
2025
Q1 | $171M | Buy |
2,674,835
+119,280
| +5% | +$12.6M | 2.66% | 12 |
|
|
2024
Q4 | $311M | Hold |
2,555,555
| – | – | 4.4% | 7 |
|
|
2024
Q3 | $319M | Sell |
2,555,555
-444,445
| -15% | -$61.4M | 4.65% | 7 |
|
|
2024
Q2 | $474M | Sell |
3,000,000
-1,344,444
| -31% | -$173M | 6.31% | 5 |
|
|
2024
Q1 | $562M | Hold |
4,344,444
| – | – | 6.56% | 4 |
|
|
2023
Q4 | $419M | Buy |
4,344,444
+319,444
| +8% | +$30.6M | 5.79% | 6 |
|
|
2023
Q3 | $488M | Sell |
4,025,000
-602,888
| -13% | -$68.1M | 7.61% | 4 |
|
|
2023
Q2 | $530M | Buy |
4,627,888
+977,888
| +27% | +$126M | 7.19% | 4 |
|
|
2023
Q1 | $503M | Buy |
3,650,000
+475,000
| +15% | +$61.6M | 7.46% | 4 |
|
|
2022
Q4 | $411M | Hold |
3,175,000
| – | – | 6.15% | 6 |
|
|
2022
Q3 | $351M | Sell |
3,175,000
-215,000
| -6% | -$21.7M | 6.48% | 5 |
|
|
2022
Q2 | $254M | Buy |
3,390,000
+255,000
| +8% | +$18.8M | 5.02% | 9 |
|
|
2022
Q1 | $245M | Buy |
3,135,000
+10,000
| +0.3% | +$766K | 4.47% | 8 |
|
|
2021
Q4 | $281M | Buy |
3,125,000
+625,000
| +25% | +$53.4M | 4.79% | 6 |
|
|
2021
Q3 | $231M | Buy |
2,500,000
+100,000
| +4% | +$7.7M | 3.63% | 7 |
|
|
2021
Q2 | $187M | Buy |
2,400,000
+250,000
| +12% | +$19M | 3.25% | 9 |
|
|
2021
Q1 | $160M | Buy |
2,150,000
+400,000
| +23% | +$36.9M | 2.77% | 11 |
|
|
2020
Q4 | $298M | Buy |
1,750,000
+75,000
| +4% | +$11.1M | 5.14% | 7 |
|
|
2020
Q3 | $235M | Hold |
1,675,000
| – | – | 3.34% | 8 |
|
|
2020
Q2 | $269M | Buy |
1,675,000
+90,000
| +6% | +$12.2M | 5.31% | 5 |
|
|
2020
Q1 | $155M | Sell |
1,585,000
-175,000
| -10% | -$20M | 5.23% | 6 |
|
|
2019
Q4 | $227M | Buy |
1,760,000
+82,000
| +5% | +$8.28M | 6.67% | 5 |
|
|
2019
Q3 | $126M | Buy |
1,678,000
+278,000
| +20% | +$32.8M | 5.27% | 7 |
|
|
2019
Q2 | $213M | Buy |
1,400,000
+205,000
| +17% | +$24.9M | 7.35% | 5 |
|
|
2019
Q1 | $142M | Sell |
1,195,000
-80,000
| -6% | -$10.3M | 6.16% | 5 |
|
|
2018
Q4 | $139M | Buy |
1,275,000
+331,500
| +35% | +$41.5M | 8.32% | 3 |
|
|
2018
Q3 | $152M | Sell |
943,500
-15,428
| -2% | -$2.11M | 7% | 3 |
|
|
2018
Q2 | $127M | Buy |
+958,928
| New | +$90.4M | 4.88% | 7 |
|
|
2017
Q1 | – | Sell |
-1,010,300
| Closed | -$27.7M | – | 50 |
|
|
2016
Q4 | $27.7M | Sell |
1,010,300
-359,609
| -26% | -$14.4M | 5.6% | 6 |
|
|
2016
Q3 | $84.1M | Sell |
1,369,909
-42,281
| -3% | -$1.28M | 14.76% | 1 |
|
|
2016
Q2 | $26.9M | Buy |
1,412,190
+257,190
| +22% | +$4.76M | 5.98% | 6 |
|
|
2016
Q1 | $22.5M | Buy |
1,155,000
+651,993
| +130% | +$11.4M | 7.87% | 4 |
|
|
2015
Q4 | $19.4M | Buy |
503,007
+33,982
| +7% | +$1.1M | 6.68% | 5 |
|
|
2015
Q3 | $15.1M | Buy |
+469,025
| New | +$15.9M | 3.92% | 11 |
|
Other funds holding SRPT
EAM
Avoro Capital Advisors's SRPT Position: Q2 2025 in Review
Avoro Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 2,674,835 shares — an estimated $171M sold.
Avoro Capital Advisors first reported a position in SRPT in Q3 2015 and held it in 34 quarters. The position peaked at $562M in Q1 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.
- Avoro Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
- Avoro Capital Advisors sold 2,674,835 Sarepta Therapeutics shares in Q2 2025, an estimated $171M.
- Avoro Capital Advisors first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 34 quarters.
- Avoro Capital Advisors's Sarepta Therapeutics position peaked at $562M in Q1 2024.
- 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.
Based on Avoro Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.